Provided by Tiger Trade Technology Pte. Ltd.

T. Rowe Price Health Care ETF

33.59
+0.37231.12%
Volume:210
Turnover:7.06K
Market Cap:32.75M
PE:- -
High:33.59
Open:33.59
Low:33.59
Close:33.22
52wk High:36.72
52wk Low:27.57
Shares:975.00K
Float Shares:975.00K
Volume Ratio:0.66
T/O Rate:0.02%
Dividend:0.16
Dividend Rate:0.48%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

UnitedHealth - 95% of Medicare-Eligible Individuals to Have Access to Hmo Plan in 2027

THOMSON REUTERS
·
Oct 01

Unitedhealthcare 2027 Medicare Plans Focus on Affordability, Simplicity and a More Connected Healthcare Experience

THOMSON REUTERS
·
Oct 01

Unitedhealthcare: 2027 Plans Offer $0 Primary Care Visits, $0 Preventive Care, $0 Tier 1 Drug Copays

THOMSON REUTERS
·
Oct 01

Unitedhealthcare: Introduces 2027 Medicare Advantage Plans; About 90% of Eligible Consumers to Have Access to $0 Premium

THOMSON REUTERS
·
Oct 01

UnitedHealthcare, Aetna Say 2027 Medicare Advantage Plans to Offer More Limited Provider Networks

Reuters
·
Oct 01

Should CHO K1 Media Launch Require Action From Thermo Fisher Scientific Stock Investors?

Simply Wall St.
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Paramount Names Kreiz as Co-CEO as Warner Bros. Deal Nears Completion

Deep News
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
Oct 01

Agilent Technologies Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Edwards Lifesciences Corp. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 01

Abbott Laboratories Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Gilead Sciences Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Oct 01

Moderna Inc. Stock Sheds 5.4%, Underperforms Peers

Dow Jones
·
Oct 01

Merck, 3M Share Losses Contribute to Dow's 286-Point Drop

Dow Jones
·
Oct 01